Head-To-Head Analysis: Opus Genetics (IRD) vs. Its Competitors

Opus Genetics (NASDAQ:IRD) is one of 1,069 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Opus Genetics to similar businesses based on the strength of its earnings, dividends, profitability, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Opus Genetics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-324.45%	-63.65%	-56.94%
Opus Genetics Competitors	-3,419.27%	-220.20%	-32.86%

Insider & Institutional Ownership

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.6% of Opus Genetics shares are held by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Opus Genetics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	0	0	1	0	3.00
Opus Genetics Competitors	8113	21760	49548	1304	2.55

Opus Genetics presently has a consensus price target of $8.00, suggesting a potential upside of 614.29%. As a group, “Pharmaceutical preparations” companies have a potential upside of 236.92%. Given Opus Genetics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Opus Genetics is more favorable than its rivals.

Volatility & Risk

Opus Genetics has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Opus Genetics’ rivals have a beta of 3.67, indicating that their average stock price is 267% more volatile than the S&P 500.

Earnings & Valuation

This table compares Opus Genetics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Opus Genetics	$19.05 million	-$9.99 million	-1.03
Opus Genetics Competitors	$1.82 billion	$140.40 million	-7.80

Opus Genetics’ rivals have higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Opus Genetics rivals beat Opus Genetics on 7 of the 13 factors compared.

Opus Genetics Company Profile

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.